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ABSTRACT
Background: Impact of splenic hilar LN dissection during total gastrectomy for 
proximal advanced gastric cancer is controversial. The objective of this study was to 
assess the impact on prognosis of splenic hilar lymph node(LN) metastasis compared 
to that of metastasis to other regional LN groups. 
Study Design: Patients who underwent total gastrectomy with D2 LN dissection 
from 2000 to 2010 were reviewed retrospectively. The clinicopathologic characteristics 
and long-term results of patients with splenic hilar LN metastasis were compared to 
those of patients with only metastasis to other extraperigastric LNs (stations #8a, 
#9, #11, or #12a). To investigate the survival benefit of performing splenic hilar 
LN dissection, the estimated therapeutic index for the procedure was calculated by 
multiplying the incidence of metastases in the hilar region by the survival rates for 
individuals with nodal involvement in that region.
Results: Of 602 patients, 87(14.5%) had hilar LN metastasis. The 5-year overall 
and relapse-free survival rates for patients with hilar LN metastasis were 24.1% and 
12.1%, respectively. These rates were similar to those for patients with metastasis 
to other extraperigastric LNs (P > 0.05), with similar recurrence patterns. Overall 
survival in the hilar LN metastasis group was better than that for patients with distant 
metastasis(P < 0.05). The estimated therapeutic index of splenic hilar LN dissection was 
3.5, which was similar to index values for LN dissection at other extraperigastric LNs.
Conclusions: Dissection of splenic hilar LNs during total gastrectomy for advanced 
gastric cancer allows for a prognosis similar to that achieved with dissection of 
extraperigastric LNs.
INTRODUCTION
Gastric cancer is the fifth most common malignancy 
and the third leading cause of cancer death in the 
world [1]. Most gastric cancer is initially diagnosed at 
the advanced disease stage except in countries that have 
mass-screening programs [1–5]. Although the incidence 
of gastric cancer worldwide has remained steady, increases 
in proximal gastric cancers, including esophagogastric 
junction cancer [6], have bolstered recommendations for 
performing total gastrectomy with D2 lymph node (LN) 
dissection for proximal advanced gastric cancer [7–9].
The reported incidence of metastasis to splenic hilar 
LNs in proximal gastric cancer ranges from 5.8 to 26.7% 
[10–16]. Thus, most treatment guidelines for proximal 
gastric cancer recommend dissection of the splenic hilar 
LNs as a regional LN group during total gastrectomy with 
D2 LN dissection [7–9]. To accomplish this dissection, 
surgeons typically perform either a splenectomy or a 
spleen-preserving technique. Although splenectomies 
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have been found to be associated with high morbidity and 
mortality, spleen-preserving hilar LN dissection can be 
technically demanding [15–18], and therefore surgeons 
are reluctant to perform splenic hilar LN dissection during 
total gastrectomy for proximal advanced gastric cancer. 
More importantly, the prognostic impact of metastasis to 
the splenic hilar LNs has yet to be determined, obscuring 
the necessity of performing splenic hilar LN dissection 
during gastrectomy.
The aim of this study was to assess the impact of 
splenic hilar LN metastasis on prognosis in gastric cancer 
patients via comparison of the recurrence patterns and 
overall and relapse-free survival rates in cases of splenic 
hilar LN metastasis with those in cases of metastasis to 
other regional LNs. We also compared overall survival for 
splenic hilar LN metastasis with that for distant metastasis. 
Lastly, we calculated and compared estimated therapeutic 
index values for splenic hilar LN dissection and dissection 
of other regional LNs.
RESULTS
Patient demographics
Of the 602 patients who underwent total 
gastrectomy with D2 LN dissection, 258 patients received 
a splenectomy, and 344 patients received splenic hilar 
LN dissection without splenectomy. Among gastrectomy 
patients, 87 (14.5%) had hilar LN metastasis, and 515 
(85.5%) had no hilar LN metastasis. The mean age of the 
LN #10-positive group versus the LN #10-negative group 
was 54.9 y versus 56.6 y (p = 0.225), with 52 (59.8%) 
versus 351 (68.2%) male patients (p = 0.124) in each group, 
respectively. Tumors from LN #10-positive patients showed 
undifferentiated histology more frequently (p = 0.002), were 
of larger size (p < 0.001), were more frequently found in the 
greater curvature of the stomach or as an encircling lesion 
(p < 0.001), comprised more Borrmann type IV cancers 
(p < 0.001), and exhibited more frequent lympho-vascular 
involvement (p < 0.001) than tumors from LN #10-negative 
patients. Although the mean number of retrieved LNs in 
the LN #10-positive group did not differ from that in the 
LN #10-negative group (56.1 vs. 52.3, p = 0.063), the 
mean number of metastatic LNs was significantly greater 
(25.5 vs. 7.0, p < 0.001) in the LN #10-positive group. As 
expected, LN #10-positive patients had more advanced T, 
N, and TNM stage cancers than LN #10-negative patients 
(p < 0.001 for all comparisons; Table 1).
Clinicopathologic characteristics were compared 
between groups with metastasis to other extraperigastric 
LNs stations (stations #8a, #9, #11, or #12a) but not to 
the splenic hilar LNs, and subgroups of patients with 
metastasis to the hilar LN #10 but not to each of the other 
stations. In this comparison, there was no patient with 
metastasis to LN #10 but not to other extraperigastric 
LN. The LN #10-positive subgroups had more advanced 
pathologic T classifications than any extraperigastric, LN 
#8a-, LN #9-, and LN #12a-positive groups (p < 0.001, 
0.011, 0.037, and < 0.001, respectively). The number 
of metastatic LNs and N classifications of the LN 
#10-positive subgroups, however, were similar to those 
for the LN #8a-, LN #9-, LN #11-, and LN #12a-positive 
groups. Overall, the LN #10-positive subgroup 
patients showed more advanced stage disease than any 
extraperigastric, LN #8a-, LN #9-, and LN #12a-positive 
patients but not LN #11-positive patients (Table 2).
Oncologic outcomes and survival analyses
Long-term follow-up over a median of 89 months 
revealed significant differences in overall survival between 
LN #10-positive patients and LN #10-negative patients 
(5-year overall survival of 24.1% vs. 54.8%, respectively, 
p < 0.001). Meanwhile, no significant differences in 
overall survival were found between patients in the LN 
#10 subgroups and those with metastasis to LN #8a, LN 
#9, LN #11, or LN #12a (5-year overall survival of 24.1% 
vs. 28.0%, p = 0.524; 28.1% vs. 26.4%, p = 0.737; 22.5% 
vs. 19.5%, p = 0.409; and 23.5% vs. 14.3%, p = 0.970, 
respectively). Overall survival in the LN #10-positive 
group was, however, better than that of LN #10-positive 
patients with distant metastasis (M1) and that of patients 
with distant metastasis but no LN #10 metastasis 
(p = 0.006 and p = 0.014, respectively; Figure 1).
With regard to relapse-free survival, LN #10-positive 
subgroup patients experienced survival similar to that 
in LN #8a-, LN #9-, LN #11-, and LN #12a-positive 
patients (5-year relapse-free survival of 17.2% vs. 20.2%, 
p = 0.737; 16.0% vs. 17.0%, p = 0.916; 19.8% vs. 9.4%, 
p = 0.426; and 12.6% vs. 7.9%, p = 0.444, respectively; 
Figure 2). Recurrence patterns in LN #10-positive patients 
were also similar to those in LN #8a-, LN #9-, LN #11-, 
and LN #12a-positive patients (p = 0.596, 0.134, 0.712, 
and 0.085, respectively; Table 3). The most common 
pattern of recurrence was peritoneal recurrence, regardless 
of involvement at any other extraperigastric LN station.
Therapeutic index of lymph node dissection at 
each lymph node station after total gastrectomy 
with D2 lymph node dissection
The incidences of metastasis and the 5-year overall 
survival rates for each LN station are provided in Figure 3. 
The incidences of LN metastasis at LN #8a, LN #9, LN 
#11, and LN #12a were 14.0%, 16.1%, 13.0%, and 2.7%, 
respectively. The incidence of metastasis to the splenic 
hilar LNs was 14.5%. The therapeutic index values of 
the estimated benefit of dissection of perigastric LN 
stations (stations #1 to #7) ranged from 2.6 to 20.7. The 
therapeutic index values for dissection of extraperigastric 
LNs (stations #8a, #9, #11, and #12a) ranged from 0.5 to 
3.8. The estimated therapeutic value of splenic hilar LN 
Oncotarget84517www.impactjournals.com/oncotarget
Table 1: Clinicopathologic factors for patients classified according to metastasis to lymph node 
station 10
Variable
LN#10 (+) 
(n = 87)
LN#10 (−) 
(n = 515)
P*
No. of 
Patients %
No. of 
Patients %
Age, years 0.225
 Mean 54.9 56.6 
 SD 13.1 12.2 
Sex 0.124
 Male 52 59.8 351 68.2 
 Female 35 40.2 164 31.8 
Splenectomy < 0.001
 Yes  56 64.4 204 39.6
 No 31 35.6 311 60.4
Operation procedure 0.407
 Open 85 97.7 489 95.0
 Minimally invasive 2 2.3 26 5.0
Histologic type 0.002
 Differentiated 10 11.5 137 26.6 
 Undifferentiated 77 88.5 378 73.4 
Tumor size, cm < 0.001
 Mean 87.1 64.2 
 SD 43.1 33.8 
Location < 0.001
 LC 28 32.2 260 50.5 
 GC 19 21.8 47 9.1 
 AW 14 16.1 76 14.8 
 PW 17 19.5 121 23.5 
 Circular 9 10.4 11 2.1 
Gross type < 0.001
 Borrmann I 4 4.6 34 6.6 
 Borrmann II 8 9.2 116 22.5 
 Borrmann III 38 43.7 252 48.9 
 Borrmann IV 35 40.2 108 21.0 
 Borrmann V 2 2.3 5 1.0 
LV invasion < 0.001
 negative 7 8.0 195 37.9 
 positive 80 92.0 320 62.1 
Number of metastatic LNs < 0.001
 Mean 25.5 7.0 
 SD 18 10.2 
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dissection was 3.5 and was calculated as follows: [0.145 
(incidence of splenic hilar LN metastasis) × 24.1 (5-year 
overall survival)]. Thus, the therapeutic index value 
of splenic hilar LN dissection was within the range of 
therapeutic index values for dissection of extraperigastric 
LN stations.
DISCUSSION
The prognosis for advanced gastric cancer patients 
with splenic hilar LN metastasis in the current study 
was similar to that for patients with any extraperigastric 
LN metastasis and better than that for those with distant 
metastasis. Relapse-free survival and patterns of recurrence 
in the patients with splenic hilar LN metastasis were also 
comparable to patients with other extraperigastric LN 
metastasis. Additionally, calculation of the therapeutic 
index of splenic hilar LN dissection during total 
gastrectomy for the treatment of proximal advanced gastric 
cancer revealed that the procedure had an impact on patient 
survival similar to dissection of other extraperigastric LNs.
Although current treatment guidelines recommend 
splenic hilar LN dissection during total gastrectomy with 
D2 LN dissection, the prognosis of patients with splenic 
hilar LN metastasis is poor. The discovery that hilar LN 
metastasis exhibits a similar prognosis to para-aortic LN 
metastasis spurred some investigators to raise questions 
regarding the stratification of splenic hilar LN as a 
extraperigastric LN and to suggest reclassifying splenic 
hilar LNs as a distant LN group [11]. In another study, 
the 5-year survival rate of patients with splenic hilar 
LN metastasis was significantly low at around 5%, even 
after curative total gastrectomy with D2 LN dissection, 
and was similar to that of patients undergoing R1 or R2 
resection. Accordingly, the authors expressed doubts 
about the therapeutic impact of removing the splenic hilar 
LNs, suggesting that no benefit exists [14]. Meanwhile, 
however, other investigators reported that in the presence 
of curative surgery, the survival of hilar LN-positive 
patients did not differ from that of hilar LN-negative 
patients, and therefore, these investigators supported 
recommendations for D2 lymphadenectomy including 
splenic hilar LN dissection [19]. Similarly, in the present 
study, the 5-year overall survival of patients with splenic 
hilar LN metastasis was 24.1% and better than that in 
patients with distant metastasis. In addition, the survival 
of patients with splenic hilar LN metastasis was similar 
to patients with other extraperigastric LN metastasis, 
Number of retrieved LNs 0.063
 Mean 56.1 52.3
 SD 17.7 17.9
T classification < 0.001
 T2 2 2.3 62 12.0 
 T3 6 6.9 121 23.5 
 T4a 67 77.0 317 61.6 
 T4b 12 13.8 15 2.9 
N classification < 0.001
 N0 0 0.0 143 27.8 
 N1 2 2.3 85 16.5 
 N2 8 9.1 107 20.8 
 N3 77 88.5 180 35.0 
TNM stage < 0.001
 Stage IB 0 0.0 37 7.2 
 Stage IIA 0 0.0 55 10.7 
 Stage IIB 3 3.5 88 17.1 
 Stage IIIA 0 0.0 84 16.3 
 Stage IIIB 11 12.6 101 19.6 
 Stage IIIC 73 83.9 150 29.1 
Abbreviations: LN, lymph node; SD, standard deviation; LC, lesser curvature; GC, greater curvature; AW, anterior wall; PW, 
posterior wall; LV, lympho-vascular. *P-values were determined for Student’s t-test or χ2 (Fisher’s exact) test for continuous 
or categorical factors, respectively.
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Figure 1: Kaplan-Meier overall survival curves for patients with splenic hilar lymph node (LN) metastasis compared 
to those with metastasis to extraperigastric LNs. (A) Compared to metastasis to any extraperigastric LN (P = 0.204). (B) Compared 
to LN #8a metastasis (P = 0.524). (C) Compared to LN #9 metastasis (P = 0.737). (D) Compared to LN #11 metastasis (P = 0.409). 
(E) Compared to LN #12a metastasis. (P = 0.970). (F) Compared to distant metastasis (M1) (P = 0.006). (G) Compared to M1 excluding 
LN #10 metastasis (P = 0.014).
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although the survival of patients with extraperigastric LN 
metastasis in this study remained poor. The poor survival 
rates in this study likely stem from the large number 
of metastatic LNs in the patients, who were stratified 
as having N3b disease according to current gastric 
cancer staging systems [20]. Moreover, around 73.6% 
(64 of 87 patients) of the patients experienced recurrence 
during follow-up after receiving curative treatment. The 
discrepancies between studies on the benefits of splenic 
hilar LN dissection probably stem from differences in the 
number of patients with LN #10 metastasis in the studies. 
Therefore, only small numbers of patients were included 
in the survival comparisons [10, 11, 14, 16]. In the current 
study, however, we included 87 patients with LN #10 
metastasis without M1 disease, thereby allowing us to 
conduct a more comprehensive analysis.
As the prognosis of splenic hilar LN metastasis 
is still under debate, we sought to investigate whether 
classification of splenic hilar LNs as a regional LN group 
is appropriate. Thus, we conducted a unique comparison 
Figure 2: Kaplan-Meier relapse-free survival curves for patients with splenic hilar lymph node (LN) metastasis 
compared to those with metastasis to extraperigastric  LNs. (A) Compared to metastasis to any extraperigastric LN (P = 0.125). 
(B) Compared to LN #8a metastasis (P = 0.737). (C) Compared to LN #9 metastasis (P = 0.916). (D) Compared to LN #11 metastasis 
(P = 0.426). (E) Compared to LN #12a metastasis (P = 0.444).
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Table 2: Clinicopathologic factors of patients with metastasis to lymph node station 10 in comparison 
to patients with exclusive metastasis to other extraperigastric LN stations
Variable
LN#10(+) 
(n = 87)
LN#10(−) 
any N2(+) 
(n = 123)
LN#10(+) 
LN#8a(−) 
(n = 54)
LN#10(−) 
LN#8a(+) 
(n = 51)
LN#10(+) 
LN#9(−)
(n = 57)
LN#10(−)
LN#9 (+) 
(n = 67)
LN#10(+)
LN#11(−) 
(n = 53)
LN#10(−)
LN#11(+) 
(n = 44)
LN#10(+)
LN#12a(−)
(n = 85)
LN#10 (−)
LN#12a (+)
(n = 14)
No. of 
Patients 
(%)
No. of 
Patients 
(%)
P*
No. of 
Patients 
(%)
No. of 
Patients 
(%)
P*
No. of 
Patients 
(%)
No. of 
Patients 
(%)
P*
No. of 
Patients 
(%)
No. of 
Patients 
(%)
P* No. of Patients (%)
No. of 
Patients 
(%)
P*
Histologic type 0.031 0.056 0.142 > 0.999 < 0.001
 Differentiated 10 (11.5) 29 (23.6) 6 (11.1) 13 (25.5) 7 (12.3) 15 (22.4) 3 (5.7) 3 (6.8) 9 (10.6) 8 (57.1)
 Undifferentiated 77 (88.5) 94 (76.4) 48 (88.9) 38 (74.5) 50 (87.7) 52 (77.6) 50 (94.3) 41 (93.2) 76 (89.4) 6 (42.9)
Tumor size, mm 0.014 0.002 0.422 0.662 0.298 
 Mean 87.1 73.1 86.4 65.4 81.7 75.9 80.3 77.2 87.2 74.6 
 SD 43.1 35.9 41.5 23.8 39.3 41.4 38.7 30.0 43.3 29.9 
Location 0.003 0.002 0.048 0.101 0.569 
 LC 28 (32.2) 67 (54.5) 17 (31.5) 32 (62.7) 19 (33.3) 35 (52.2) 16 (30.2) 23 (52.3) 27 (31.8) 6 (42.9)
 GC 19 (21.8) 12 (9.8) 13 (24.1) 3 (5.9) 12 (21.1) 11 (16.4) 14 (26.4) 4 (9.1) 19 (22.3) 1 (7.1)
 AW 14 (16.1) 18 (14.6) 9 (16.7) 6 (11.8) 10 (17.5) 12 (17.9) 11 (20.8) 6 (13.6) 14 (16.5) 4 (28.6)
 PW 17 (19.6) 23 (18.7) 10 (18.5) 10 (19.6) 11 (19.3) 9 (13.4) 8 (15.1) 8 (18.2) 16 (18.8) 2 (14.3)
 Circular 9 (10.3) 3 (2.4) 5 (9.2) 0 (0) 5 (8.8) 0 (0) 4 (7.5) 3 (6.8) 9 (10.6) 1 (7.1)
Number of 
metastatic LN
< 0.001 0.207 0.125 0.716 0.135 
 Mean 25.5 15.7 20.8 17.0 23.3 18.7 20.6 19.4 25.2 17.4
 SD 18 13.3 15.4 15.4 17.9 15.4 15.8 16.3 17.4 12
Number of 
retrieved LN
0.309 0.515 0.763 0.775 0.085 
 Mean 56.1 53.5 54.9 52.7 56.4 55.4 51.5 52.5 55.8 47.2
 SD 17.7 19 16.6 17.1 16.8 22.3 15.7 16.3 17.2 16.4
T classification < 0.001 0.011 0.037 0.553 < 0.001
 T2 2 (2.3) 5 (4.1) 2 (3.7) 3 (5.9) 2 (3.5) 2 (3.0) 2 (3.8) 1 (2.3) 2 (2.4) 0 (0)
 T3 6 (6.9) 24 (19.5) 2 (3.7) 7 (13.7) 4 (7.0) 14 (20.9) 4 (7.5) 3 (6.8) 5 (5.9) 7 (50.0)
 T4a 67 (77.0) 92 (74.8) 43 (79.6) 41 (80.4) 44 (77.2) 49 (73.1) 40 (75.5) 38 (86.4) 66 (77.6) 7 (50.0)
 T4b 12 (13.8) 2 (1.6) 7 (13.0) 0 (0) 7 (12.3) 2 (3.0) 7 (13.2) 2 (4.5) 12 (14.1) 0 (0)
N classification 0.065 0.583 0.491 0.809 > 0.999
 N1 2 (2.3) 6 (4.9) 2 (3.7) 1 (1.9) 2 (3.5) 3 (4.5) 1 (1.9) 2 (4.5) 2 (2.4) 0 (0)
 N2 8 (9.2) 24 (19.5) 8 (14.8) 11 (21.6) 6 (10.5) 12 (17.9) 7 (13.2) 5 (11.4) 8 (9.4) 1 (7.1)
 N3 77 (88.5) 91 (75.6) 44 (81.5) 39 (76.5) 49 (86.0) 52 (77.6) 45 (84.9) 37 (84.1) 75 (88.2) 13 (92.9)
TNM stage 0.001 0.059 0.013 0.237 0.001 
 Stage IIA 0 (0) 1 (0.8) 0 (0) 1 (2.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Stage IIB 3 (3.5) 4 (3.2) 3 (5.5) 1 (2.0) 3 (5.3) 2 (3.0) 3 (5.7) 1 (2.3) 3 (3.5) 0 (0)
 Stage IIIA 0 (0) 13 (10.6) 0 (0) 4 (7.8) 0 (0) 8 (11.9) 0 (0) 3 (6.8) 0 (0) 0 (0)
 Stage IIIB 11 (12.6) 27 (22.0) 7 (13.0) 11 (21.6) 7 (12.3) 13 (19.4) 7 (13.2) 4 (9.1) 10 (11.8) 8 (57.1)
 Stage IIIC 73 (93.9) 78 (63.4) 44 (81.5) 34 (66.6) 47 (82.4) 44 (65.7) 43 (81.1) 36 (81.8) 72 (84.7) 6 (42.9)
Abbreviations: LN, lymph node; SD, standard deviation; LC, lesser curvature; GC, greater curvature; AW, anterior wall; PW, posterior wall; LV, lympho-vascular. *P-values were calculated from Student’s 
t-test or χ2 (Fisher’s exact) test for continuous or categorical factors, respectively.
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of splenic hilar LN metastasis with metastasis to other 
extraperigastric LNs, as well as distant metastasis, in terms 
of survival and recurrence patterns. In this comparison, the 
extraperigastric LN metastasis groups (LN #8a, #9, #11, 
and #12a, according to JGCA classification [7], which did 
not have hilar LN metastasis, showed similar long-term 
prognoses and recurrence patterns to patients with hilar LN 
metastasis. Although, there was no patient with metastasis 
to LN #10 without any extraperigastric LN metastasis, 
which might indicate splenic hilar LN was the farthest 
regional LN or boundary LN between the extraperigastric 
and distant LN, the survival between the patients with 
metastasis to LN #10 and those with metastasis to 
any extraperigastric but not to LN #10 metastasis did 
not significantly different. Additionally, the estimated 
therapeutic index value for splenic hilar LN dissection 
Table 3: Recurrence patterns
Groups Locoregional Hematogenous Distant LN Peritoneal Mixed P
LN#10+ (n = 64) 3 (4.7)* 8 (12.5) 4 (6.3) 37 (57.8) 12 (18.8)
0.389
LN#10− (n = 212) 5 (2.4) 36 (17.0) 21 (9.9) 125 (59.0) 25 (11.8)
LN#10+ (n = 64) 3 (4.7) 8 (12.5) 4 (6.3) 37 (57.8) 12 (18.8)
0.506
LN#10-AnyN2+ (n = 87) 2 (2.3) 13 (14.9) 12 (13.8) 48 (55.2) 12 (13.8)
LN#10+LN#8− (n = 37) 2 (5.4) 4 (10.8) 2 (5.4) 22 (59.5) 7 (18.9)
0.596
LN#10-LN#8+ (n = 36) 1 (2.8) 5 (13.9) 6 (16.7) 19 (52.8) 5 (13.9)
LN#10+LN#9− (n = 41) 3 (7.3) 7 (17.1) 2 (4.9) 22 (53.7) 7 (17.1)
0.134
LN#10−LN#9+ (n = 50) 0 (0) 10 (20.0) 9 (18.0) 24 (48.0) 7 (14.0)
LN#10+LN#11− (n = 36) 0 (0) 5 (13.9) 3 (8.3) 23 (63.9) 5 (13.9)
0.712
LN#10-LN#11+ (n = 37) 1 (2.7) 3 (8.1) 6 (16.2) 22 (59.5) 5 (13.5)
LN#10+LN#12a− (n = 62) 3 (4.8) 7 (11.3) 4 (6.5) 37 (59.7) 11 (17.7)
0.085
LN#10−LN#12a+ (n = 11) 0 (0) 3 (27.3) 0 (0) 3 (27.3) 5 (45.5)
*Values in parentheses are percentages.
Figure 3: Estimated benefit of lymph node (LN) dissection by calculating therapeutic index. Therapeutic index was 
calculated by multiplying the frequency of metastases by 5-year survival rates for individuals with nodal involvement at that specific 
station, regardless of nodal metastases to any other LN station.
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(3.5) was comparable to values for extraperigastric LN 
dissection (0.5–3.8). In support of these results, other 
studies have also reported similar therapeutic index values, 
ranging from 2.4–3.8, for LN #10 dissection of upper third 
gastric cancer [11, 21]. Taken together, these findings 
suggest that splenic hilar LNs should indeed continue to 
be classified as a regional LN group.
A recent Japanese multicenter prospective study 
(JCOG 0110) that examined splenectomy versus 
spleen-preservation during total gastrectomy for 
clinically advanced gastric cancer revealed no benefit of 
splenectomy in terms of operative safety and survival [22]; 
however, the study excluded tumors of the greater 
curvature, although these tumors are generally candidates 
for splenic hilar LN dissection. Thus, the study included 
clinically advanced gastric cancer patients who had little 
possibility of splenic hilar LN metastasis. Also, a large 
number of patients with pathologic T1 or N0 cancer was 
also included. Therefore, from these results alone, the 
actual therapeutic impact of splenic hilar LN dissection 
on advanced gastric cancer in patients with LN #10 
involvement would be difficult to determine. In our study, 
however, we focused explicitly on the prognosis of splenic 
hilar LN metastasis, demonstrating acceptable survival 
and recurrence as well as a similar prognostic impact for 
splenic hilar LN dissection in comparison to dissection of 
metastases to other extraperigastric LNs. 
Although current guidelines indicate D2 LN 
dissection, including splenic hilar LN dissection, for 
advanced (T2 or more advanced) gastric cancer during 
total gastrectomy, alterations of these indications to reflect 
tumor characteristics warrants discussion. As shown in this 
study, as well as in previous reports, significantly larger 
tumors, Borrmann type IV tumors, and advanced stage 
tumors involving the greater curvature or entire stomach 
were prominent in the hilar LN metastasis group [10–13, 
15, 16, 23]. In addition, 96.5% (84/87) of patients who had 
hilar LN metastasis were staged IIIB or IIIC in the current 
study, while only 1.1% (3/267) of patients with hilar LN 
metastasis were staged IB to IIIA. A recent randomized 
controlled trial revealed no hilar LN metastasis in stage 
IIIA tumors or less advanced tumors that were staged 
according to the 6th TNM staging system, similar to our 
study [24]. Therefore, tumors not involving the greater 
curvature of the stomach that are small in size and of 
earlier stages may not warrant hilar LN dissection.
In our study, the indications for splenic hilar LN 
dissection likely varied among surgeons. In addition, the 
indications for either splenectomy or spleen-preserving 
hilar LN dissection could not be discerned, as this decision 
was made at the surgeon’s discretion. The splenectomy 
group consisted of patients who had tumors of larger size 
at the greater curvature or circular location and were of 
advanced T classification/TNM stage. This group also 
included patients with a larger number of metastatic LNs 
(Table 4, Supplement). These characteristics reflected 
the poor survival outcomes in the splenectomy group 
(Figure 4, Supplement). Also, picking up LN #10 after 
spleen-preserving hilar LN dissection is difficult, although 
one surgeon who participated in the operation picked up 
each station just after the operation before sending it to 
the pathologist. As a potential consequence thereof, we 
obtained a significant difference in the number of retrieved 
LNs between splenectomy and spleen-preservation. 
Moreover, although we typically divide LN bearing tissue 
around the bifurcation of the upper or lower polar splenic 
artery from the main splenic artery to discriminate LN #10 
from LN #11d, it can be difficult to divide them clearly. 
Additionally, there is the possibility that the actual number 
of retrieved LNs after spleen-preserving hilar LN dissection 
would be less, because posterior aspects of splenic vessels 
can be difficult to reach. This study also did not account for 
postoperative adjuvant chemotherapy, which may have an 
impact on patient survival. In general, patients with stage 
II or higher disease receive postoperative chemotherapy in 
accordance with our institution’s standard postoperative 
care. Despite these limitations, this study included a 
large number of patients who underwent standard D2 
Figure 4: (Supplement). Kaplan-Meier survival curves for patients who underwent spleen-preserving hilar lymph node dissection and 
splenectomy. (A) Overall survival. (B) Relapse-free survival. 
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Table 4: (Supplement)
Variable
Spleen-preservation (n = 342) Splenectomy (n = 260)
P*No. of 
Patients %
No. of 
Patients %
Age, years 0.467
 Mean 56.0 56.8 
 SD 12.4 12.1 
Sex 0.377
 Male 234 68.4 169 65.0 
 Female 108 31.6 91 35.0 
Histologic type 0.634
 Differentiated 86 25.1 61 23.5 
 Undifferentiated 256 74.9 199 76.5 
Tumor size, cm < 0.001
 Mean 6.1 7.5 
 SD 3.4 3.8 
Location 0.009
 LC 172 50.3 116 44.6 
 GC 30 8.8 36 13.8 
 AW 51 14.9 39 15.0 
 PW 84 24.6 54 20.8 
 Circular 5 1.4 15 5.8 
Gross type 0.203
 Borrmann I 21 6.2 17 6.5 
 Borrmann II 63 18.4 61 23.5 
 Borrmann III 179 52.3 111 42.7 
 Borrmann IV 75 21.9 68 26.1 
 Borrmann V 4 1.2 3 1.2 
LV invasion 0.033
 negative 127 37.1 75 28.8 
 positive 215 62.9 185 71.2 
Number of metastatic LNs < 0.001
 Mean 8.0 11.9
 SD 11.4 15.2
Number of retrieved LNs 0.231
 Mean 52.1 53.8
 SD 17.4 18.5
LN #10 involvement
 positive 31 9.1 56 21.5 
 negative 311 90.9 204 78.5 
Number of metastatic LNs at LN #10 < 0.001
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LN dissection by experienced surgeons at a high-volume 
medical center. The results are significant because these 
findings encompass both therapeutic and prophylactic LN 
dissection for the treatment of proximal advanced gastric 
cancer. We discovered that patients with advanced gastric 
cancer with splenic hilar LN metastasis experience similar 
survival to those with other extraperigastric LN metastasis. 
These results suggest that splenic hilar LNs should be 
regarded as a regional LN group during total gastrectomy 
for the treatment of proximal advanced gastric cancer.
MATERIALS AND METHODS
Using a prospective database, we identified 2,453 
patients who underwent total gastrectomy for gastric 
adenocarcinoma from 2000 to 2010 at Severance Hospital, 
Yonsei University Medical Center. Individual clinical and 
pathologic tumor characteristics, as well as short- and long-
term patient outcomes, were retrieved. From the original 
cohort, 1,694 patients were excluded: 93 patients received 
preoperative chemotherapy with or without radiotherapy, 
627 patients had T1 tumors, 906 patients did not undergo D2 
LN dissection, and 68 patients had no information on splenic 
hilar LN metastasis (Figure 5). The final study population 
comprised 759 patients, among which 602 underwent 
curative total gastrectomy with D2 LN dissection. Of these 
patients, 87 out of 602 had splenic hilar LN metastasis 
and 157 had distant metastasis (M1) who received 
palliative total gastrectomy either splenic hilar lymph node 
dissection or not. Of all 157 patients with distant metastasis, 
112 peritoneal metastases or Krukenberg tumors, 32 
hematogenous metastases, six distant LNs metastases, and 
seven mixed metastases were included. Clinicopathologic 
characteristics, including age, sex, histologic differentiation, 
tumor size, location, gross type, lympho-vascular invasion, 
number of metastatic and retrieved LNs, and tumor-node-
metastasis (TNM) stages, were included in the analyses. 
This retrospective study was approved by the Institutional 
Review Board of Severance Hospital, Yonsei University 
College of Medicine (4-2015-0951).
Extent of lymphadenectomy
Total gastrectomy with D2 LN dissection was 
performed in accordance with the Japanese Gastric Cancer 
Association (JGCA) classification guidelines [7].
 Mean 0.2 0.6
 SD 0.6 1.7
Number of retrieved LNs at LN #10 < 0.001
 Mean 2.0 3.1
 SD 2.1 3.4
T classification < 0.001
 T2 43 12.6 21 8.1 
 T3 100 29.2 27 10.4 
 T4a 192 56.1 192 73.8 
 T4b 7 2.1 20 7.7 
N classification 0.092
 N0 88 25.7 55 21.2 
 N1 56 16.4 31 11.9 
 N2 66 19.3 49 18.8 
 N3 132 38.6 125 48.1 
TNM stage < 0.001
 Stage IB 26 7.6 11 4.2 
 Stage IIA 47 13.8 8 3.1 
 Stage IIB 48 14.0 43 16.5 
 Stage IIIA 50 14.6 34 13.1 
 Stage IIIB 63 18.4 49 18.9 
 Stage IIIC 108 31.6 115 44.2 
Comparison of clinicopathologic factors between spleen-preserving hilar LN dissection and splenectomy patient groups.
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Indications for splenectomy or spleen-preserving 
hilar LN dissection
At our institution, splenectomy during total 
gastrectomy with D2 LN dissection is indicated for 
gastric cancers with definite splenic hilar LN enlargement 
or direct invasion to the gastrosplenic ligament or the 
spleen. Spleen-preserving hilar LN dissection is indicated 
for gastric cancers with no serosal involvement and no 
evidence of gross LN metastasis along the splenic artery 
or splenic hilum during preoperative and intraoperative 
evaluation [17, 25]. We previously published our standard 
procedures for performing open or minimally invasive 
total gastrectomy with D2 LN dissection [25, 26].
Indications for minimally invasive surgery
Patients with preoperative diagnosis of suspicious 
proper muscle invasion were indicated for total gastrectomy 
with D2 LN dissection, using either conventional 
laparoscopy or a robotic surgical system, since 2003 
and 2005, respectively. Patients with evidence of serosal 
involvement or patients with any evidence of gross LN 
metastasis along the splenic artery or hilum were not 
generally considered to be indicated for minimally invasive 
surgery. All patients suitable for minimally invasive 
surgery were informed about procedures, including open 
gastrectomy and the risks and benefits of each procedure. 
All patients were allowed to select the type of operation 
that they would undergo, and all gave informed consent for 
the surgical method at the time of operation. 
Prognostic impact of splenic hilar LN metastasis
To evaluate the impact of splenic hilar LN 
metastasis on prognosis in gastric cancer patients, the 
survival of patients with metastasis to splenic hilar LNs 
(LN station #10) was compared to that of patients with 
metastasis to other extraperigastric LNs (e.g., LN stations 
#8a, #9, #11, or #12a) who did not concurrently have 
splenic hilar LN metastasis. For example, patients with 
metastasis to LN station #10 without metastasis to LN 
Figure 5: Study profile.
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station #12a were compared to patients with metastasis to 
LN station #12a without metastasis to LN station #10. We 
also compared survival of the patients with metastasis to 
LN station #10 without metastasis to any extraperigastric 
LN to any extraperigastric LN station without LN station 
#10 metastasis. The overall survival curve of the splenic 
hilar metastasis group was compared to that of patients 
with distant metastasis (n = 157) and patients with distant 
metastasis without splenic hilar LN metastasis (n = 135).
Estimated therapeutic index of splenic hilar LN 
dissection for gastric cancer
The estimated therapeutic index was first proposed 
as a means to estimate the benefit of removing an LN 
during surgery [21]. The index is calculated by multiplying 
the incidence of metastases by 5-year survival rates for 
individuals with nodal involvement at that specific station, 
regardless of nodal metastases to any other LN station.
Patterns of recurrence
Patterns of recurrence were defined as locoregional, 
hematogenous, distant, peritoneal, and mixed, as in 
previous reports [27, 28].
Statistical analysis
Clinicopathologic and short- and long-term operative 
results, including recurrence and survival, were analyzed 
using the Statistical Package for Social Sciences software, 
version 20.0 (IBM, Armonk, NY, USA). During the study 
period, patients were followed from the date of surgery until 
December 31, 2014 or their death. Overall survival was 
calculated from the date of operation to the last follow-up or 
death from any cause. Relapse-free survival was calculated 
from the date of operation to recurrence of gastric cancer 
or death from any cause. The date of recurrence was 
recorded as the day on which recurrence was confirmed 
by any imaging modality or tissue confirmation. Patients 
not experiencing the relevant end points were censored 
at last follow-up. Five-year overall survival and relapse-
free survival were calculated using the Kaplan-Meier 
method, and differences in these rates between groups 
were examined using the log-rank test. Categorical and 
continuous variables were analyzed by the χ2 or Fisher’s 
exact and Student’s t-test, respectively. P-values < 0.05 
(two-sided) were considered statistically significant.
Abbreviations
LN = lymph node; JGCA = Japanese Gastric Cancer 
Association; JCOG = Japan Clinical Oncology Group.
Authorsʼ contributions
Taeil Son and In Gyu Kwon contributed equally 
to this work. TS, IGK, and WJH designed the study. TS, 
IGK, and JHL collected the data. TS, IGK, HIK, and WJH 
conducted the statistical analyses. TS, IGK, and WJH 
wrote the paper. JHL, YYC, JHC, and SHN critically 
revised subsequent drafts. All authors read and approved 
the submitted version.
ACKNOWLEDGMENTS
We would like to thank Anthony Thomas Milliken, 
ELS (Editing Synthase, Seoul, Korea) for his assistance 
with editing the manuscript. We also acknowledge the 
assistance of BioScience Writers, LLC (Houston, TX, USA) 
with copyediting and correction of English language usage.
CONFLICTS OF INTEREST
All authors declare no conflicts of interest.
FUNDING
All authors have completed the disclosure 
declaration, and none of the authors or their immediate 
family members report a conflicting financial interest. 
This study was supported by a grant from the National 
R&D Program for Cancer Control, Ministry of Health & 
Welfare, Republic of Korea (1320270).
REFERENCES
 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, 
Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 
2015; 65:87–108.
 2. Kong SH, Park DJ, Lee HJ, Jung HC, Lee KU, Choe KJ, 
Yang HK. Clinicopathologic features of asymptomatic 
gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol. 
2004; 34:1–7.
 3. Kim YG, Kong SH, Oh SY, Lee KG, Suh YS, Yang JY, 
Choi J, Kim SG, Kim JS, Kim WH, Lee HJ, Yang HK. 
Effects of screening on gastric cancer management: 
comparative analysis of the results in 2006 and in 2011. 
J Gastric Cancer. 2014; 14:129–134.
 4. Everett SM, Axon AT. Early gastric cancer in Europe. Gut. 
1997; 41:142–150.
 5. Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, 
Calingaert B. Treatment Patterns, Costs, and Survival 
among Medicare-Enrolled Elderly Patients Diagnosed 
with Advanced Stage Gastric Cancer: Analysis of a Linked 
Population-Based Cancer Registry and Administrative 
Claims Database. J Gastric Cancer. 2015; 15:87–104.
 6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising 
incidence of adenocarcinoma of the esophagus and gastric 
cardia. JAMA. 1991; 265:1287–1289.
 7. Japanese gastric cancer treatment guidelines 2014 (ver. 4). 
Gastric Cancer. 2016; 20:1–19.
Oncotarget84528www.impactjournals.com/oncotarget
 8. Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, 
Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, 
Hayman JA, Hofstetter WL, Ilson DH, et al. Gastric cancer, 
version 2.2013: featured updates to the NCCN Guidelines. 
J Natl Compr Canc Netw. 2013; 11:531–546.
 9. Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, 
Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, 
Kim YS, et al. Synopsis on clinical practice guideline of 
gastric cancer in Korea: an evidence-based approach. 
Korean J Gastroenterol. 2014; 63:66–81.
10. Mönig SP, Collet PH, Baldus SE, Schmackpfeffer K, 
Schröder W, Thiele J, Dienes HP, Hölscher AH. 
Splenectomy in proximal gastric cancer: frequency of 
lymph node metastasis to the splenic hilus. J Surg Oncol. 
2001; 76:89–92.
11. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, 
Nagano Y, Fujii S, Akiyama H, Nomura M, Otsuka Y, 
Ono HA, Kosaka T, Takagawa R, et al. Impact of 
splenectomy in patients with gastric adenocarcinoma of the 
cardia. J Gastrointest Surg. 2007; 11:1039–1044.
12. Maruyama K, Gunvén P, Okabayashi K, Sasako M, 
Kinoshita T. Lymph node metastases of gastric cancer. General 
pattern in 1931 patients. Ann Surg. 1989; 210:596–602.
13. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, 
Sohn TS, Bae JM, Kim S. Clinical significance of splenic 
hilar lymph node metastasis in proximal gastric cancer. Ann 
Surg Oncol. 2009; 16:1304–1309.
14. Zhu GL, Sun Z, Wang ZN, Xu YY, Huang BJ, Xu Y, Zhu Z, 
Xu HM. Splenic hilar lymph node metastasis independently 
predicts poor survival for patients with gastric cancers in the 
upper and/or the middle third of the stomach. J Surg Oncol. 
2012; 105:786–792.
15. Maehara Y, Moriguchi S, Yoshida M, Takahashi I, 
Korenaga D, Sugimachi K. Splenectomy does not correlate 
with length of survival in patients undergoing curative 
total gastrectomy for gastric carcinoma. Univariate and 
multivariate analyses. Cancer. 1991; 67:3006–3009.
16. Yu W, Choi GS, Chung HY. Randomized clinical trial of 
splenectomy versus splenic preservation in patients with 
proximal gastric cancer. Br J Surg. 2006; 93:559–563.
17. Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, 
Min JS. Impact of splenectomy for lymph node dissection 
on long-term surgical outcome in gastric cancer. Ann Surg 
Oncol. 2001; 8:402–406.
18. Hyung WJ, Lim JS, Song J, Choi SH, Noh SH. 
Laparoscopic spleen-preserving splenic hilar lymph node 
dissection during total gastrectomy for gastric cancer. J Am 
Coll Surg. 2008; 207:e6–11.
19. Ikeguchi M, Kaibara N. Lymph node metastasis at the 
splenic hilum in proximal gastric cancer. Am Surg. 2004; 
70:645–648.
20. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, 
Trotti A. American Joint Committee on Cancer (AJCC). 
AJCC cancer staging manual. 7th ed. New York. Springer, 
2010.
21. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New 
method to evaluate the therapeutic value of lymph node 
dissection for gastric cancer. Br J Surg. 1995; 82:346–351.
22. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, 
Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, 
Fukushima N, Fujitani K. Randomized Controlled Trial to 
Evaluate Splenectomy in Total Gastrectomy for Proximal 
Gastric Carcinoma. Ann Surg. 2017; 265:277–283.
23. Koga S, Kaibara N, Kimura O, Nishidoi H, Kishimoto H. 
Prognostic significance of combined splenectomy or 
pancreaticosplenectomy in total and proximal gastrectomy 
for gastric cancer. Am J Surg. 1981; 142:546–550.
24. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, 
Maluenda F. A prospective randomized study comparing 
D2 total gastrectomy versus D2 total gastrectomy plus 
splenectomy in 187 patients with gastric carcinoma. 
Surgery. 2002; 131:401–407.
25. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, Chung HC, 
Choi SH, Noh SH. The effect of spleen-preserving 
lymphadenectomy on surgical outcomes of locally advanced 
proximal gastric cancer. J Surg Oncol. 2009; 99:275–280.
26. Son T, Lee JH, Kim YM, Kim HI, Noh SH, Hyung WJ. 
Robotic spleen-preserving total gastrectomy for gastric cancer: 
comparison with conventional laparoscopic procedure. Surg 
Endosc. 2014; 28:2606–2615.
27. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence 
following curative resection for gastric carcinoma. Br 
J Surg. 2000; 87:236–242.
28. Song J, Lee HJ, Cho GS, Han SU, Kim MC, Ryu SW, 
Kim W, Song KY, Kim HH, Hyung WJ. Recurrence 
following laparoscopy-assisted gastrectomy for gastric 
cancer: a multicenter retrospective analysis of 1,417 
patients. Ann Surg Oncol. 2010; 17:1777–1786.
